New drug combo aims to keep rare skin cancer from returning
NCT ID NCT07400302
First seen Feb 15, 2026 · Last updated May 05, 2026 · Updated 10 times
Summary
This study is for people with a rare type of skin cancer called mucosal melanoma that has been completely removed by surgery and tests positive for PD-L1. The trial compares the effects of adding the immunotherapy drug sintilimab to standard chemotherapy versus chemotherapy alone after surgery. The main goal is to see if the combination helps keep the cancer from coming back longer. About 220 participants will take part in this phase 2 study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1 POSITIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.